What are the current ACC/AHA guidelines for the management of heart failure?
Current ACC/AHA guidelines for the management of heart failure recommend that thiazolidinediones be avoided or discontinued in patients with HF (Class III Recommendation: Harm; Level of Evidence B). Similarly, scientific advisories caution against the use of rosiglitazone or pioglitazone in all patients with signs and symptoms of HF. Initiation of either agent is contraindicated in patients with class III to IV HF.